Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running
OSAKA, Japan--(BUSINESS WIRE)--Jan 21, 2020--
Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK ) (“Takeda”) is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive year. Corporate Knights assesses more than 7,300 companies against 21 key performance indicators. It uses these indicators to determine the top 1% most sustainable companies in the world, which are announced annually at the World Economic Forum in Davos, Switzerland.
“Building sustainable value is a fundamental part of the way we do business at Takeda, and we are proud to be recognized as a global leader in sustainability,” said Christophe Weber, President and CEO. “This recognition by Corporate Knights is a testament to the strong foundation Takeda has laid and the progress we have already achieved. We remain steadfast in our commitment to realizing Better Health and a Brighter Future for all.”
Corporate Knights highlighted Takeda’s performance in the following areas:
In addition to the Global 100 index, Takeda is recognized by many other environmental, social and governance (ESG) investment valuations. As a long-standing member of the United Nations Global Compact, Takeda’s sustainability efforts are guided by key international targets, such as the Sustainable Development Goals (SDGs).
Dow Jones Sustainability World Index
1 st year
Dow Jones Sustainability Asia Pacific Index
10 th year
FTSE4Good Developed Index
15 th consecutive year
MSCI ESG Leaders Index
10 th consecutive year
Ethibel EXCELLENCE Investment Register
Since July 2017
2 nd consecutive year
Industry Mover Sustainability Yearbook Award 2019
Since February 2019
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit www.takeda.com
About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/
View source version on businesswire.com:https://www.businesswire.com/news/home/20200120005554/en/
CONTACT: Japanese Media
+81 (0) 3-3278-2095Media outside of Japan
KEYWORD: SWITZERLAND CANADA JAPAN NORTH AMERICA ASIA PACIFIC EUROPE
INDUSTRY KEYWORD: ENVIRONMENT WOMEN HUMAN RESOURCES PROFESSIONAL SERVICES PHILANTHROPY BIOTECHNOLOGY PHARMACEUTICAL CONSUMER HEALTH OTHER PHILANTHROPY
SOURCE: Takeda Pharmaceutical Company Limited
Copyright Business Wire 2020.
PUB: 01/21/2020 12:00 AM/DISC: 01/21/2020 12:00 AM